IL6 and susceptibility to pneumonia measurement: Ticagrelor administration to patients within 48h of pneumonia diagnosis demonstrated anti-inflammatory effect with reduced PLAs in circulation, lowered IL-6 levels and improved lung function with a decrease in supplemental oxygen requirements [113].